Kazia Therapeutics Limited American Depositary Shares KZIA

$7.98 -1.24% at last close

Analyst Consensus

Consensus Rating
Buy (8 Buy · 0 Hold · 0 Sell)
Average Price Target
$29.50
Implied Upside
+269.7%
Price Target Range
$18.00 – $40.00
Analysts (12 mo)
8

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-10-30
NeedhamGil Blum
Initiates coverage on Buy $27
2026-10-21
GuggenheimPaul Jeng
Initiates coverage on Buy $35
2026-10-20
Leerink PartnersAndrew Berens
Initiates coverage on Outperform $30
2026-09-10
BTIGKambiz Yazdi
Reiterates Buy $40
2026-09-01
BTIGKambiz Yazdi
Maintains Buy $34 → $40
2026-08-13
Canaccord GenuityJohn Newman
Initiates coverage on Buy $29
2026-07-15
BTIGKambiz Yazdi
Reiterates Buy $34
2026-07-01
BTIGKambiz Yazdi
Initiates coverage on Buy $34
2026-06-11
Lake Street
Initiates coverage on Buy $32
2026-04-15
Laidlaw & Co.Yale Jen
Initiates coverage on Buy $25
2026-01-28
HC Wainwright & Co.Sean Lee
Reiterates Buy $18
2025-12-12
HC Wainwright & Co.Sean Lee
Maintains Buy $13 → $18
2025-10-02
Maxim GroupNaz Rahman
Maintains Buy $15 → $20
2025-07-10
HC Wainwright & Co.Sean Lee
Maintains Buy $2 → $13
2025-06-11
Maxim GroupJason McCarthy
Maintains Buy $15
2025-02-06
Maxim GroupJason McCarthy
Initiates coverage on Buy $15
2024-07-12
HC Wainwright & Co.Sean Lee
Reiterates Buy $100
2023-04-11
HC Wainwright & Co.Sean Lee
Upgrades Neutral → Buy $100
2022-08-02
Maxim GroupJason McCarthy
Downgrades Buy → Hold —
2022-08-02
HC Wainwright & Co.Sean Lee
Downgrades Buy → Neutral —
2021-10-14
Maxim GroupNaureen Quibria
Initiates coverage on Buy $900
2021-01-05
HC Wainwright & Co.Sean Lee
Initiates coverage on Buy $850

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$7.98
Market Cap
$125.63 million
52-Week Range
$4.86 – $17.40
Average Volume
222K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.